Biotechnology News and Research

RSS

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Algatechnologies launches AstaPure 20% astaxanthin oleoresin

Algatechnologies Ltd., a leading manufacturer and supplier of natural algae astaxanthin announces the launch of AstaPure 20% astaxanthin oleoresin. This content of astaxanthin exceeds any available in the marketplace.

7 Apr 2014

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Helping doctors monitor their melanoma patients' progress in response to treatment is just one of the many exciting applications of Bio-Rad's Droplet Digital PCR (ddPCR-) technology being showcased at the 2014 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9.

7 Apr 2014

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

7 Apr 2014

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

...

7 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

UH Math collaborates with Rice on synthetic gene circuit

A long-standing challenge in synthetic biology has been to create gene circuits that behave in predictable and robust ways. Mathematical modeling experts from the University of Houston (UH) collaborated with experimental biologists at Rice University to create a synthetic genetic clock that keeps accurate time across a range of temperatures.

7 Apr 2014

Bio-Techne makes $10M equity investment in CyVek

Techne Corporation, d/b/a Bio-Techne, announced today that it has made a $10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future milestones are met.

4 Apr 2014

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.

4 Apr 2014

Metabolon announces launch of fourth-generation metabolomics platform

Metabolon, Inc., a leader in metabolomics-driven biomarker discovery, announced today the launch of DiscoveryHD4, the company's fourth-generation metabolomics platform.

4 Apr 2014

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc., announced today that it has co-led a $4.1 million Series A private equity financing of Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders.

3 Apr 2014

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

Europe's pharmaceutical research community to convene at PRO & eCOA Congress

The most progressive minds in Europe's pharmaceutical research community will convene at the PRO & eCOA Congress, Europe 3-5 June in Barcelona, Spain.

3 Apr 2014

QIAGEN launches new products for next-generation sequencing applications

QIAGEN N.V. today announced two important new product launches which address workflow challenges in next-generation sequencing (NGS) applications.

From QIAGEN Manchester Limited 3 Apr 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.

3 Apr 2014

BIO and WLSA to explore intersection between digital health and biotechnology at 2014 BIO International Convention

The Biotechnology Industry Organization (BIO) and the Wireless-Life Sciences Alliance (WLSA) today announced a partnership to explore the intersection between digital health and biotechnology through the inaugural Digital Health Zone and Forum at the 2014 BIO International Convention®.

3 Apr 2014

Affygility’s occupational exposure limit monograph is now available for delta-9-tetrahydrocannabinol

Affygility Solutions is pleased to announce that its occupational exposure limit monograph is now available for delta-9-tetrahydrocannabinol, the principal psychoactive ingredient in marijuana.

3 Apr 2014

UM researchers awarded FDA contract to expand high-throughput sequencing database

Researchers at the Institute for Genome Sciences at the University of Maryland School of Medicine have been awarded a research program contract from the U.S. Food and Drug Administration (FDA) to sequence, assemble, and annotate a population of bacterial pathogens using two high-throughput sequencing (HTS) technologies in support of the expansion of a vetted public reference database.

2 Apr 2014

Evotec signs research collaboration and licensing deal with Debiopharm Group

Evotec AG announced today a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

2 Apr 2014

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

The Cedars-Sinai Regenerative Medicine Institute has received a $2.5 million grant from the Department of Defense to conduct animal studies that, if successful, could provide the basis for a clinical trial of a gene therapy product for patients with Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS.

2 Apr 2014

Biotechnology News and Research

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Algatechnologies launches AstaPure 20% astaxanthin oleoresin

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

UH Math collaborates with Rice on synthetic gene circuit

Bio-Techne makes $10M equity investment in CyVek

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Metabolon announces launch of fourth-generation metabolomics platform

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Europe's pharmaceutical research community to convene at PRO & eCOA Congress

QIAGEN launches new products for next-generation sequencing applications

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

BIO and WLSA to explore intersection between digital health and biotechnology at 2014 BIO International Convention

Affygility’s occupational exposure limit monograph is now available for delta-9-tetrahydrocannabinol

UM researchers awarded FDA contract to expand high-throughput sequencing database

Evotec signs research collaboration and licensing deal with Debiopharm Group

Cedars-Sinai earns grant to conduct clinical trial of gene therapy product for patients with Lou Gehrig's disease

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News